Tobias Neef
Northwestern University
11 Papers
5 Citations
Tobias Neef is an academic researcher from Northwestern University. The author has contributed to research in topics: Immune system & Antigen. The author has an hindex of 4, co-authored 5 publications.
Chat about Author
Papers
Tolerogenic Ag-PLG Nanoparticles Induce Tregs to Suppress Activated Diabetogenic CD4 and CD8 T Cells
Suchitra Prasad,Tobias Neef,Dan Xu,Joseph R. Podojil,Daniel R. Getts,Lonnie D. Shea,Stephen D. Miller +6 more
TL;DR: The ability of carboxylated 500 nm biodegradable poly(lactide-co-glycolide) nanoparticles PLG nanoparticles (either surface coupled with or encapsulating the cognate diabetogenic peptides) to rapidly and efficiently restore tolerance in NOD is demonstrated.
94
Biodegradable antigen-associated PLG nanoparticles tolerize Th2-mediated allergic airway inflammation pre- and postsensitization.
Charles B. Smarr,Woon Teck Yap,Tobias Neef,Ryan M. Pearson,Zoe Hunter,Igal Ifergan,Daniel R. Getts,Paul J. Bryce,Lonnie D. Shea,Stephen D. Miller +9 more
TL;DR: In this paper, antigen-associated nanoparticles (Ag-NPs) were used to prevent and treat Th1/Th17-mediated autoimmune disease, and they were also effective for the induction of tolerance in a murine model of Th2-mediated ovalbumin/alum-induced allergic airway inflammation.
89
Nanoparticles Containing an Insulin-ChgA Hybrid Peptide Protect from Transfer of Autoimmune Diabetes by Shifting the Balance between Effector T Cells and Regulatory T Cells.
Braxton L. Jamison,Tobias Neef,Andrew Goodspeed,Brenda Bradley,Rocky L. Baker,Stephen D. Miller,Kathryn Haskins +6 more
TL;DR: This work is the first to use a hybrid insulin peptide, or any neoepitope, to re-educate diabetogenic T cells and may have significant implications for the development of an Ag-specific therapy for type 1 diabetes patients.
Tolerogenic Nanoparticles to Treat Islet Autoimmunity.
Tobias Neef,Stephen D. Miller +1 more
TL;DR: The topic is reviewed and recent strategies to produce tolerogenic nanoparticles for the purpose of treating T1D are highlighted, with a greater focus on how to translate this technology from preclinical use in mice to treatment of type 1 diabetes in humans.
23
Tolerogenic Immune-Modifying Nanoparticles Encapsulating Multiple Recombinant Pancreatic β Cell Proteins Prevent Onset and Progression of Type 1 Diabetes in Nonobese Diabetic Mice
Joseph R. Podojil,Samantha Genardi,Ming-Yi Chiang,Sandeep Kakade,Tobias Neef,Tushar Murthy,Michael T. Boyne,Adam Elhofy,Stephen D. Miller +8 more
TL;DR: Tolerance to individual epitopes/proteins fails to inhibit T1D development, and CNP treatment is both safe and induced Ag-specific tolerance in a phase 1/2a celiac disease clinical trial, suggesting Ag- specific tolerance induced by nanoparticles encapsulating multiple diabetogenic proteins is a promising approach to T1d treatment.